Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTEA.L Regulatory News (CTEA)

  • There is currently no data for CTEA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity & Proposed Directorate Change

31 Jan 2020 13:36

RNS Number : 6180B
Catenae Innovation PLC
31 January 2020
 

CATENAE INNOVATION PLC

("Catenae" or the "Company")

 

Subscription, conversion of existing liabilities, conditional issue of warrants and proposed directorate change

Following the recent announcements about the Company's weak working capital position Catenae announces that it has issued 75,000,000 new ordinary shares in the Company by way of a subscription and conversion of existing liabilities in the Company. The shares to be issued pursuant to the subscription and conversion will use the shareholder authorities granted at the general meeting held by the Company on 23 December 2019.

Subscription and conditional issue of warrants

The Company has raised £153,000 through the subscription (the "Subscription") for 38,250,000 new ordinary shares ("Subscription Shares") at a price of 0.4 pence per share (the "Subscription Price"). The Subscription Shares are subject to a six-month lock-in expiring six months following their issue. The Subscription Shares represent circa 35.7 per cent. of the enlarged share capital.

The Company has agreed, subject to shareholder approval at a forthcoming General Meeting of the Company, to issue each subscriber a warrant to subscribe for the same number of ordinary shares subscribed for in the Subscription ("Subscription Warrants"). The Subscription Warrants are exercisable for a period of 2 years from issue at the Subscription Price. Subscription Warrants over 38,250,000 ordinary shares have been conditionally issued.

Guy Meyer, Interim CEO and a director of the Company, has subscribed for 2,000,000 (£8,000) shares in the Subscription and pursuant to the AIM Rules, is a related party transaction (the "Transaction"). Independent Director, Kevin Everett, having consulted with the Company's Nominated Adviser, believes that the terms of the Transaction are fair and reasonable insofar as shareholders are concerned.

Conversion and conditional issue of warrants

Certain of the Company's creditors have agreed to convert their existing liabilities into ordinary shares (the "Conversion"). Consequently the Company has issued 36,750,000 new ordinary shares at a price of 1.1p per share (the "Conversion Shares") in order to settle aggregate liabilities of £404,250. The Conversion Shares are subject to a six-month lock-in expiring 6 months following their issue. The Conversion Shares represent circa 18.8 per cent. of the enlarged share capital.

The Conversion has the impact of strengthening the Company's Balance Sheet and allows the Company to use its cash resources to fund current and potential trading opportunities.

The Company has conditionally agreed to grant warrants over 20,159,091 new ordinary shares to certain creditors in relation to the Conversion ("Conversion Warrants"). The Conversion Warrants are exercisable for a period of 2 years from issue at the Subscription Price. The issue of the Conversion Warrants is subject to shareholder authorities being granted at a forthcoming General Meeting of the Company.

Included in the Conversion detailed above is the issue of 1,158,3649 ordinary shares to Cloisters Capital LLP ("Cloisters" or "Cloisters' Conversion"). Cloisters is an entity controlled by John Farthing, Chief Financial Officer. Mr Farthing is not a director of the Company. Mr Farthing is considered a PDMR (Person Discharging Management Responsibility). The conversion is in relation to professional fees owed to Cloisters. Further details of the issue are set out in a table at the end of this announcement.

The Cloisters' Conversion is considered a related party transaction pursuant to the AIM Rules as Mr Farthing is a director of a joint venture of the Company. The directors of the Company, having consulted with the Company's nominated adviser, believe that the terms of the Cloisters' Conversion are fair and reasonable insofar as shareholders are concerned.

Admission of Shares to Trading on AIM

Application has been made for the 75,000,000 new ordinary shares, constituting the Subscription Shares and the Conversion Shares, to be admitted to trading on AIM, which is expected to occur on or around 6 February 2020. The 75,000,000 new ordinary shares will rank pari passu with the existing ordinary shares.

Proposed Directorate Change

Brian William Thompson has subscribed for 25,000,000 new ordinary shares in the Subscription and, in addition, has been issued 5,681,818 Conversion Shares in relation to a creditor balance owed to him, which, when aggregated with his existing holding in the Company, will represent circa 29.0 per cent of the enlarged issued share capital.

It is intended that, subject to the completion of normal regulatory due diligence, Mr Thompson will be appointed as a non-executive director of the Company.

Mr Thompson is an entrepreneur and is the founder owner of Newcastle-based B.T.I.C. Ltd, a successful business that has operated in the insurance industry since 1985. He is also a director of Third Eye Neurotech Ltd.

Further disclosure on Mr Thompson will be made in due course.

Working capital update

The Subscription and Conversion eases the Company's immediate working capital position and provides the Company with funds to continue trading and meet its liabilities as they fall due in the short term. The directors estimate that the Company will be likely to need to raise further funds by 31 March 2020. The Company will shortly convene a General Meeting seeking the requisite shareholder authorities to, inter alia, issue new shares.

The Company's balance sheet has been further strengthened as a result of circa £130,000 payroll related liabilities having being waived.

The current directors have also reduced their remuneration to conserve the cash resources of the Company.

Following the Subscription, Conversion and waiver of payroll related liabilities as described above, the Company's working capital position will still need to be carefully managed.

General Meeting

As stated above, the Company will be seeking the consent of shareholders at a General Meeting for, inter alia, renewed authorities for directors to be able to issue further shares and the grant of the Conversion Warrants.

Total voting rights

The Company's total issued share capital prior to this announcement was 32,236,017 ordinary shares of 0.2p each.

Following the Subscription and Conversion described above the Company's total issued share capital will comprise 107,236,017 ordinary shares. The above figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged for release of this announcement on behalf of the Company was Guy Meyer (Interim Chief Executive Officer).

 

 

Catenae Innovation Plc

Guy Meyer

 

 

Tel: 020 7929 7826

Cairn Financial Advisers LLP, Nominated Adviser

Liam Murray / Jo Turner

 

Tel: 020 7213 0880

Turner Pope Investments (TPI) Limited Broker

Andrew Thacker / Zoe Alexander

Tel: 020 3657 0050

Yellow Jersey, PR & IR Adviser

Charles Goodwin

Tel: 020 3004 9512

 

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

(1)John Farthing

(2) Guy Meyer

2

Reason for notification

a.

Position/Status

(1) Chief Financial Officer

(2) Interim CEO

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Catenae Innovation plc

b.

LEI

2138007I2D8YWPMSP544

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.2p each

 

GB00BKM6CG53

b.

Nature of the transaction

Issue of ordinary shares

c.

Price(s) and volume(s)

Price(s) per share

Volume(s)

(1) 1.1 pence

(2) 0.4 pence

 

(1) 1,158,369

(2) 2,000,000

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

(1) 1,158,364

(2) 2,000,000

 

(1) 1.1 pence

(2) 0.4 pence

 

e.

Date of the transaction

31 January 2020

f.

Place of the transaction

AIM

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSDEFDFESSEDF
Date   Source Headline
1st Jul 20203:12 pmRNSTotal Voting Rights
1st Jul 20202:06 pmRNSSecond Price Monitoring Extn
1st Jul 20202:00 pmRNSPrice Monitoring Extension
1st Jul 20207:00 amRNSCompletion of Cov-ID Project
30th Jun 20207:01 amRNSHalf-year Report
30th Jun 20207:00 amRNSFinal Results
26th Jun 20204:30 pmRNSExercise of Warrant
23rd Jun 20204:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20204:36 pmRNSPrice Monitoring Extension
19th Jun 20207:00 amRNSCov-ID Project Update
12th Jun 20209:58 amRNSIssue of Equity
11th Jun 20202:02 pmRNSShare Price Movement and Update
10th Jun 202012:30 pmRNSExercise of Warrant, Conversion & Issue of Equity
3rd Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20207:00 amRNSHolding(s) in Company
29th May 202012:24 pmRNSHolding(s) in Company
29th May 20207:00 amRNSAgreement with Newcastle Premier Health Ltd
28th May 20204:41 pmRNSSecond Price Monitoring Extn
28th May 20204:35 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSExercise of Warrant and Issue of Equity
18th May 20207:00 amRNSCov-ID Project Update
14th May 202012:49 pmRNSResult of General Meeting and Issue of Equity
1st May 20209:00 amRNSUpdate - Cov-ID Project
29th Apr 20205:09 pmRNSPosting of Circular and Notice of General Meeting
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSDirectorate Changes
23rd Apr 202012:19 pmRNSHolding(s) in Company
21st Apr 20202:05 pmRNSSecond Price Monitoring Extn
21st Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20203:32 pmRNSConditional Placing to raise £320,000 and Update
17th Apr 20207:00 amRNSCatenae joins Consortium on Cov-ID Project
16th Apr 20205:30 pmRNSChange of Broker
31st Mar 20202:45 pmRNSHolding(s) in Company
31st Mar 20202:40 pmRNSHolding(s) in Company
31st Mar 20202:35 pmRNSHolding(s) in Company
31st Mar 20207:00 amRNSAnnual Report, Trading & COVID-19 Update
26th Mar 202012:49 pmRNSWorking Capital Facility
31st Jan 20201:36 pmRNSIssue of Equity & Proposed Directorate Change
24th Jan 20201:20 pmRNSUpdate re Working Capital & Balance Sheet
10th Jan 202012:23 pmRNSUpdate re Working Capital & Balance Sheet
23rd Dec 201911:37 amRNSResult of General Meeting
20th Dec 20195:02 pmRNSUpdate re Working Capital
20th Dec 20191:23 pmRNSFurther re Share Capital & Timetable Update
20th Dec 20197:00 amRNSShare Capital and Total Voting Rights
19th Dec 20197:00 amRNSFurther re Agreements and update
6th Dec 201910:53 amRNSPosting of Circular and Notice of General Meeting
12th Sep 201910:50 amRNSHolding(s) in Company
11th Sep 20197:30 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.